Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Townsend sold 3,295 shares of the stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $3.26, for a total transaction of $10,741.70. Following the transaction, the chief executive officer directly owned 373,483 shares in the company, valued at approximately $1,217,554.58. This represents a 0.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Lexeo Therapeutics Stock Performance
Shares of NASDAQ LXEO traded up $0.09 during midday trading on Wednesday, hitting $2.95. 1,763,182 shares of the stock traded hands, compared to its average volume of 1,241,679. Lexeo Therapeutics, Inc. has a one year low of $2.55 and a one year high of $10.99. The company has a market cap of $242.04 million, a PE ratio of -2.36 and a beta of 1.64. The business has a 50 day moving average price of $3.31 and a two-hundred day moving average price of $4.96.
Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last released its quarterly earnings results on Monday, November 16th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.11). As a group, equities research analysts forecast that Lexeo Therapeutics, Inc. will post -1.22 EPS for the current fiscal year.
Institutional Investors Weigh In On Lexeo Therapeutics
Hedge funds have recently bought and sold shares of the business. Lighthouse Investment Partners LLC purchased a new position in shares of Lexeo Therapeutics during the 3rd quarter worth about $39,000. Marshall Wace LLP acquired a new stake in Lexeo Therapeutics in the third quarter valued at approximately $840,000. Empowered Funds LLC acquired a new stake in Lexeo Therapeutics in the third quarter worth about $199,000. Aberdeen Group plc grew its holdings in shares of Lexeo Therapeutics by 90.5% during the third quarter. Aberdeen Group plc now owns 1,286,077 shares of the company's stock valued at $4,347,000 after buying an additional 610,985 shares during the last quarter. Finally, Signaturefd LLC boosted its holdings in shares of Lexeo Therapeutics by 5,159.1% in the 3rd quarter. Signaturefd LLC now owns 8,362 shares of the company's stock valued at $28,000 after acquiring an additional 8,203 shares during the last quarter. Hedge funds and other institutional investors own 60.67% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts recently commented on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Lexeo Therapeutics in a research note on Wednesday, November 11th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Lexeo Therapeutics in a research note on Thursday, November 12th. Raymond James Financial reiterated a "strong-buy" rating on shares of Lexeo Therapeutics in a report on Monday. Chardan Capital raised Lexeo Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 28th. Finally, Wall Street Zen cut shares of Lexeo Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $16.43.
Get Our Latest Stock Report on LXEO
Lexeo Therapeutics Company Profile
(
Get Free Report)
Lexeo Therapeutics, Inc. is a clinical-stage biotechnology company developing gene therapies for inherited cardiovascular and other serious diseases. Its research focuses on using genetic medicines to address conditions caused by specific gene mutations. The company's investigational programs include LX2006, a gene therapy being studied for Friedreich ataxia cardiomyopathy, and other candidates targeting genetically defined heart diseases. These therapies remain in development and are not established commercial products.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lexeo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexeo Therapeutics wasn't on the list.
While Lexeo Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.